TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06159218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CEST - coiled oesophageal string test
Description: All patients will swallow a small string (CEST) which will be removed and then analysed for biomarkers and microbiome.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CEST - coiled oesophageal string test
Description: All patients will swallow a small string (CEST) which will be removed and then analysed for biomarkers and microbiome.
Study: NCT05861167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: selective intensive induction therapy based on ustekinumab clinical decision-making tools
Description: At week 0 and week 8, UST was induced intravenously twice (stratified according to body weight, see instructions for dosage), and at the third time, intravenous or standard subcutaneous injection regimen was used according to CRP standard
Study: NCT05261698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Exercise Manual
Description: in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: In this group patients will receive routine physical therapy including hot pack for 10 minutes, stretching, strengthening exercise and TENS at the end of each session.
Study: NCT03507946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermawrap - combined 460nm, 633nm and 830nm LED therapy
Description: Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
Study: NCT06311877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mBerry
Description: mBerry tablets (.4 grams), which contain protein within the miracle berry called miraculin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: The control group will not received intervention.
Study: NCT04783090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: bispecific peptide as a CaSR agonist and a functional OGP analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: bispecific peptide as a CaSR agonist and a functional OGP analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: bispecific peptide as a CaSR agonist and a functional OGP analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: bispecific peptide as a CaSR agonist and a functional OGP analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: bispecific peptide as a CaSR agonist and a functional OGP analogue
Study: NCT05936697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fNIRS
Description: For fNIRS to be recorded by the wearable OctaMon+ system (Artinis Medical Systems, The Netherlands), two sources, each surrounded by four detectors positioned approximately 3 cm apart, will be placed on the scalp such that the two channels near the fissure on each side of the head are surrounded F3 and F4. Data will be sampled at 50 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: For EEG to be recorded by the ANT eego rt8 amplifier (ANT Neuro, Hengelo, The Netherlands), electrodes will be placed at Fp1, F3, F4, Fz, Fpz, Cz, GND (ground), lower VEOG, and on the two earlobes (references). Data will be collected at 2,048 Hz.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Baseline Training
Description: In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity within and across sessions.
Study: NCT05349799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA® 1
Description: During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will not receive any additional treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (needle)
Description: During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a needle. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (cannula)
Description: During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a cannula. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5).
Study: NCT05055206

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT-CT
Description: 99m-Technetium Sulfur Colloid will be injected prior to the scan.
Study: NCT05014867

Intervention type: PROCEDURE
Intervention: Embryo transfer method
Description: 1. Sequential embryo transfer on day 3 and day 5 in a frozen cycle~2. Sequential embryo transfer on day 3 and day 5 in a fresh cycle~3. Sequential embryo transfer on day 3 and day 5 after performing PGS~4. Conventional Day 5 frozen embryo transfer

Intervention type: PROCEDURE
Intervention: Embryo transfer method
Description: 1. Sequential embryo transfer on day 3 and day 5 in a frozen cycle~2. Sequential embryo transfer on day 3 and day 5 in a fresh cycle~3. Sequential embryo transfer on day 3 and day 5 after performing PGS~4. Conventional Day 5 frozen embryo transfer

Intervention type: PROCEDURE
Intervention: Embryo transfer method
Description: 1. Sequential embryo transfer on day 3 and day 5 in a frozen cycle~2. Sequential embryo transfer on day 3 and day 5 in a fresh cycle~3. Sequential embryo transfer on day 3 and day 5 after performing PGS~4. Conventional Day 5 frozen embryo transfer

Intervention type: PROCEDURE
Intervention: Embryo transfer method
Description: 1. Sequential embryo transfer on day 3 and day 5 in a frozen cycle~2. Sequential embryo transfer on day 3 and day 5 in a fresh cycle~3. Sequential embryo transfer on day 3 and day 5 after performing PGS~4. Conventional Day 5 frozen embryo transfer
Study: NCT05867498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent exercise
Description: Strength component (circuit-based exercise) and aerobic component (based on musicalized and outdoor activities).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Low-to-moderate-intensity continuous training and interval training based on musicalized and outdoor activities.
Study: NCT06279208

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Recovery of plasma from the bottom of a blood collection tube.

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Recovery of plasma from the bottom of a blood collection tube.
Study: NCT05953233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active classroom HEPA cleaner
Description: Commercially available portable HEPA cleaner

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham classroom HEPA cleaner
Description: Commercially available portable HEPA cleaner with filtration device removed
Study: NCT05890716

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-powered ECG analysis to detect cardiac arrhythmic episodes
Description: ECG recording and processing by AI platform

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-powered ECG analysis to detect cardiac arrhythmic episodes
Description: ECG recording and processing by AI platform
Study: NCT05063656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 8 weeks of gabapentin, titrated up to 20 mg/kg in 3 divided doses daily
Study: NCT05915481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Participants will receive SBRT to one lesion or more lesions.
Study: NCT04949321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
Description: Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
Study: NCT06210321

Intervention type: OTHER
Group type: OTHER
Intervention: Prescription of escitalopram using pharmacogenetic testing
Description: Adjustment of escitalopram treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \*2, \*3 and \*17)
Study: NCT05079243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Scaffold and adipose-derived stromal cell enriched fat grafts
Description: eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer
Study: NCT05852613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high power laser therapy (HPLT)
Description: high power laser therapy (HPLT) will be produced by A LEVELASER EZ1 EASYONE device which produces a Ga Al As CW diode laser with pulsed emission 980 nm and maximum average power 5 W with a high level of energy penetration. While the patient is in a prone position and the head slightly bends to the front, The treatment will be performed at a distance of 60-70 cm, perpendicular to the cervical region, in a pulsed mode of 4 Hz, wavelength = 980 nm, radiation power density P = 4 W in the scan phase and 2 W in the acupuncture phase and energy 840 J. Patients will receive pulsed HPLT laser treatment for 8 minutes. Scanning will be performed transversely and longitudinally to the bilateral paraspinal muscles, inter-scapular area, upper trapezius and the neck region for 6 minutes followed by 2 minutes acupuncture. Protective goggles will be used to prevent direct eye contact of the laser beam.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Description: hot pack, US for 5 min, exercise for 20 min.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: selected physical therapy program
Description: hot pack, US for 5 min, exercise for 20 min.
Study: NCT04626167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concomitant Renal and Urinary Bladder Allograft Transplantation
Description: This is a single-center, prospective, single-group unblinded phase I study that will enroll subjects with chronic kidney disease secondary to bladder dysfunction or bladder absence that is refractory to medical treatment and requires surgical intervention to prevent long-term sequelae. Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or contruction.
Study: NCT00012844

Intervention type: DEVICE
Group type: OTHER
Intervention: Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed
Study: NCT05826171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Exercise Prior to Balance Training
Description: 20-30 minutes of high intensity aerobic exercise followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 weeks (16 sessions total). For the aerobic component, participants will be instructed in a 20-30-minute exercise program, using available equipment already located in the participant's home (eg. stationary cycle, elliptical trainer, etc). Exercise intensity is moderate-to-high (between 50-85% Heart Rate Reserve. Participants will be placed on a ramped protocol which increases in intensity slowly over the course of the intervention period. For the balance training component, exercises will consist of steady state, proative, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Exercise Prior to Balance Training
Description: 20-30 minutes of light intensity warm-up type exercises, followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 week (16 sessions total). For the warm-up exercise component, exercises will consist of stretching and core training. For the balance training component, exercises will consist of steady state, proactive, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses throughout. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.~Both groups are matched for time and frequency of intervention components.
Study: NCT06114667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilatory support via nasal high flow
Description: Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilatory support via NIV
Description: Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
Study: NCT04993157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIA586
Description: FIA586 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIA586
Description: FIA586 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIA586
Description: FIA586 capsule
Study: NCT04802577

Intervention type: DIAGNOSTIC_TEST
Intervention: FACT-F questionnaire
Description: The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: FACT-F questionnaire
Description: The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Depression Inventory
Description: The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Depression Inventory
Description: The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Anxiety Inventory
Description: The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Anxiety Inventory
Description: The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Insomnia severity index.
Description: The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Insomnia severity index.
Description: The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.

Intervention type: OTHER
Intervention: ESSPRI
Description: The questionnaire, based on patient report outcome data in which the severity of Sjögren's syndrome is investigated in participants.

Intervention type: OTHER
Intervention: ESSDAI
Description: Activity scale in which the activity of Sjögren's syndrome is evaluated based on the laboratory and imaging tests of the patients and the examination findings of the evaluator.

Intervention type: OTHER
Intervention: Pain Detect Questionnaire
Description: The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.

Intervention type: OTHER
Intervention: Pain Detect Questionnaire
Description: The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.
Study: NCT06245096

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Sessions will focus on skills such as behavioral activation, mood tracking, identifying and reframing automatic thoughts, assertion training and smart goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: Sessions will focus on skills such as mindfulness, acceptance and willingness training, values clarification, committed action, defusion, and self-as-context.
Study: NCT06425042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: Participants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will ingest 1g/d of placebo orally during 12 weeks in parallel to a exercise training program
Study: NCT06060327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.
Study: NCT05418543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound with fine needle biopsy
Description: Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound with fine needle biopsy
Description: Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
Study: NCT03492918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.~All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
Study: NCT05522491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: All subjects enrolled will receive olaparib.Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
Study: NCT05519722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation-focused online intervention
Description: Patients receive an expectation-focused online intervention (around 30 minutes) consisting of a video with general information about psychotherapy, a video with reports of patients' therapy experiences, questions on the content of the videos as well as open questions on personal strengths, fears and expectations in the context of therapy. This intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the psychotherapeutic process.
Study: NCT04835506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: infliximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: infliximab
Study: NCT05809297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser combined with photodynamic-red laser therapy by RapidoPodia Laser Diodo®
Description: According to the manufacturer's recommendations, the treatment will be carried out in consultation in 8 sessions by a specialised podiatrist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer
Description: The application of Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer will be performed at home by the patient once a day.
Study: NCT06086340

Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib with an aromatase inhibitor therapy

Intervention type: DRUG
Intervention: Aromatase Inhibitor
Description: Aromatase Inhibitor Therapy

Intervention type: DRUG
Intervention: Aromatase Inhibitor
Description: Aromatase Inhibitor Therapy